Morphometric Characterization of Rat and Human Alveolar Macrophage Cell Models and their Response to Amiodarone using High Content Image Analysis by Hoffman, Ewelina et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1007/s11095-017-2176-5
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Hoffman, E., Patel, A., Ball, D., Klapwijk, J., Millar, V., Kumar, A., ... Hutter, V. (2017). Morphometric
Characterization of Rat and Human Alveolar Macrophage Cell Models and their Response to Amiodarone using
High Content Image Analysis. Pharmaceutical Research, 1-11. DOI: 10.1007/s11095-017-2176-5
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
RESEARCH PAPER
Morphometric Characterization of Rat and Human Alveolar
Macrophage Cell Models and their Response to Amiodarone
using High Content Image Analysis
Ewelina Hoffman1,2 & Aateka Patel3,4 & Doug Ball5 & Jan Klapwijk5 & Val Millar6 & Abhinav Kumar3 &
Abigail Martin1 & Rhamiya Mahendran1 & Lea Ann Dailey3,7 & Ben Forbes3 & Victoria Hutter1
Received: 2 March 2017 /Accepted: 8 May 2017
# The Author(s) 2017. This article is an open access publication
ABSTRACT
Purpose Progress to the clinic may be delayed or prevented
when vacuolated or Bfoamy^ alveolar macrophages are ob-
served during non-clinical inhalation toxicology assessment.
The first step in developing methods to study this response
in vitro is to characterize macrophage cell lines and their re-
sponse to drug exposures.
Methods Human (U937) and rat (NR8383) cell lines and
primary rat alveolar macrophages obtained by bronchoalve-
olar lavage were characterized using high content fluores-
cence imaging analysis quantification of cell viability, mor-
phometry, and phospholipid and neutral lipid accumulation.
Results Cell health, morphology and lipid content were com-
parable (p < 0.05) for both cell lines and the primary macro-
phages in terms of vacuole number, size and lipid content.
Response s to amiodarone , a known inducer o f
phospholipidosis, required analysis of shifts in cell population
profiles (the proportion of cells with elevated vacuolation or
lipid content) rather than average population data which was
insensitive to the changes observed.
Conclusions A high content image analysis assay was de-
veloped and used to provide detailed morphological char-
acterization of rat and human alveolar-like macrophages
and their response to a phospholipidosis-inducing agent.
This provides a basis for development of assays to predict
or understand macrophage vacuolation following inhaled
drug exposure.
KEY WORDS foamymacrophage . NR8383 . toxicology .
U937 . vacuolation
ABBREVIATIONS
BAL Bronchoalveolar lavage
DMEM/F12 Dulbecco’s modified Eagle’s
medium/Ham’s F12
DMSO Dimethyl sulphoxide
FBS Fetal bovine serum
FCCP Carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone
K-F12 Kaighn’s modified Ham’s F12
NO Nitric oxide
NR8383 Rat alveolar macrophage cell line
PBS Phosphate buffered saline
PMA Phorbol myristate acetate
RPMI-1640 Roswell Park Memoral Institute medium
SD Standard deviation
TNFα Tumour necrosis factor alpha
TX-100 Triton X-100
U937 Human lung monocyte cell line
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INTRODUCTION
Airway diseases such as asthma and chronic obstructive pulmo-
nary disease (COPD) are an area of unmet clinical need despite
considerable investment in developing new therapeutics in this
area [1, 2]. New inhaled medicines require extensive non-
clinical safety assessment before progressing to the clinic for
evaluation of safety and efficacy in humans [1–6]. It is not un-
common for alveolar macrophage responses to be observed in
histological lung slices of animals during non-clinical inhalation
toxicology studies: these are typically characterised by a highly
vacuolated appearance and larger cell size [2, 3]. These cell
responses may be unaccompanied by other changes or may be
associated with other immune cell infiltration or remodelling of
lung tissue [2, 3]. As themechanism for induction of this alveolar
macrophage phenotype and its relation to lung pathophysiology
are not well understood, safe exposure levels are set without
knowing whether these observations are truly an adverse re-
sponse or an adaptation to high doses [2–4]. Due to these con-
cerns over safety, inhaled compounds may fail in human studies
due to lack of efficacy at the doses permitted [3–5].
BFoamy macrophage^ is a term used by pathologists to
describe an alveolar macrophage with a vacuolated cytoplasm
when viewed by light microscopy [1, 2]. Currently, there are
no universally accepted criteria to differentiate whether this
vacuolated appearance constitutes an adaptive (non-adverse)
or an adverse response. It is hypothesized that inhaled drugs
may induce the foamy appearance in alveolar macrophages
via different pharmacological and non-pharmacological
mechanisms [7–10]. For example, a vacuolated appearance
may be an appearance common to a reversible response due
to the uptake of poorly soluble inhaled drug particulates or
indicative of an inimical disruption of metabolic activity [1–4].
The need to understand macrophage responses mechanis-
tically and develop techniques to identify ‘problem’ molecules
early during development and discriminate these from agents
that induce non-adverse macrophage responses is well recog-
nized [3]. Validated tools with this capability would improve
the efficiency of drug development process by identifying poor
drug candidates early and removing barriers to the clinical
translation of good drug candidates. Such a scientific,
evidence-based approach would also align with 3R principles
and reduce the burden of animal testing by reducing the need
to perform or repeat in vivo toxicology studies, especially if
in vitro methodologies can be developed. In vitro strategies for
screening new drug compounds for their propensity to induce
a macrophage vacuolation and study the mechanistic basis of
the vacuolated state have been recently reported [7].
Discerning the different mechanisms by which the vacuolated
phenotypes develop and resolve is key to understanding the
safety implications of this phenomenon.
The high content analysis screen proposed recently by
Hoffman et al. utilized fluorescence imaging of untreated
and drug-treated murine macrophages to generate morpho-
metric data (cell and nuclear area, vacuole number, vacuole
size) alongside cell viability and functionality data (mitochon-
drial activity, membrane permeability, phagocytosis, activa-
tion state) [7]. This preliminary study was designed to com-
pare the morphometric and functional properties of in vitro
murine macrophages, J774A.1 cells in response to selected
drug challenges [7].
The current study describes development of the fluorescence
imaging methodology to obtain quantitative morphometric da-
ta across three cell types (rat and human cell lines versus primary
rat alveolar macrophages). Early in vivo pre-clinical safety and
efficacy studies for new inhaled drug candidates in the pharma-
ceutical industry are predominantly conducted in the rat [1–3].
The NR8383 rat macrophage cell line is well established and is
widely used for in vitro inhalation toxicity prediction studies
[8–10]. In the absence of a specific human alveolar macrophage
cell line being commercially available, U937 cells (human
monocytes derived from a pleural effusion) were employed be-
ing the only humanmonocyte cell line to originate from the lung
and were differentiated to macrophages using established pro-
tocols [11–16]. These cell sources were selected to represent rat
and human species and make comparisons between the rat cell
line and primary rat alveolar macrophages. The aim of the
study was to develop the high content methodology reported
previously [7], to include cell health, morphometric data and
lipid profiling within the same 96-well format. The assay was
used to characterize the two cell lines cultured using standard
conditions reported in the literature and compare vacuolation
profiles of the cells in the unperturbed state and following expo-
sure to a well-known foamy macrophage inducer compound,
amiodarone [17–29], for 24 and 48 h. Algorithms for
converting images into morphometric data were developed
and the most sensitive statistical parameters to reflect cell popu-
lation responses were established. The results reported here
document important information on the baseline condition of
the cell lines, comparison with rat primary alveolar macro-
phages under the same assay conditions, and provide the basis
from which to develop an in vitro predictive assay for vacuolated
macrophage induction.
MATERIALS AND METHODS
Cell Culture
Rat macrophage (NR8383) and human monocyte (U937) cell
lines were purchased from LCG Standards (Teddington,
Middlesex, UK) and used between passage 2 and 20 from pur-
chase. NR8383 cells were cultured as described previously by
others [8–10]. In brief, cells were cultured in Kaighn’s modified
Ham’s F12 (K-F12) medium with 15% v/v heat-inactivated
fetal bovine serum (FBS) and supplemented with 100 IU/ml
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penicillin-100 μg/ml streptomycin solution and 2 mM L-
glutamine (Sigma Aldrich, Dorset, UK). U937 cells were cul-
tured as previously described in literature [11–16]. In summary,
cells were maintained in RPMI with 10% v/v FBS and supple-
mented with 100 IU/ml penicillin-100 μg/ml streptomycin so-
lution and 2 mM L-glutamine (Sigma Aldrich, Dorset, UK).
U937 cells were cultured in a humidified atmosphere at 37°C
with 5% v/v CO2 and cell number was maintained between 1 x
105 to 2 x 106 cells/ml. For experiments, cells were seeded onto
bottom μclear black 96-well plates (Greiner Bio-One,
Gloucester, UK) at an optimal density of 3 x 104 cells/well in
100 μl of complete cell culture medium. The cell density was
determined experimentally to ensure equal cell distribution in
the well for optimal image capture. U937 cells were differenti-
ated to a macrophage phenotype using 4 nM phorbol myristate
acetate (PMA) (Sigma Aldrich, Dorset, UK) in complete cell
culture media for 96 h followed by a 24 h rest period in com-
plete cell culture medium as previously described [16].
Rat Alveolar Macrophages Obtained from Lavage
Male Wistar Han rats were supplied by Charles River between
7–9 weeks of age (approximately 250–300 g). Alveolar macro-
phages were obtained according to established methodology
[28]. In brief, the trachea of naïve rats was isolated by a midline
incision, cannulated and the lungs washed with 3 x 5 mL bron-
choalveolar lavage (BAL) fluid (3.72 g ethylenediaminetetraacetic
acid /1 g bovine serum albumin/L in phosphate buffered saline
(PBS)). The individual aliquots from each animal were combined
to form one BAL sample per animal and stored on wet ice. The
samples were centrifuged at 250 g for 5 min at 4°C. Cells pellets
were re-suspended in 1 mL of complete culture medium as
outlined for U937 cells above. For experiments, primary alveolar
macrophages cells were obtained from naïve rats after two
timepoints (day 1 and day 7) of an in vivo study due to the limited
quantity of alveolar macrophages available from BAL. No dif-
ferences were anticipated between cells isolated on different days
of the in vivo study. These cells were seeded onto bottom μclear
black 96-well plates (Greiner Bio-One, Gloucester, UK) at a
density of 1.5 x 104 cells/well in 100 μL of complete cell culture
medium. The plate was centrifuged at 380 g for 5 min at 20°C
and the cells incubated for 2 h in a humidified atmosphere at
37°C with 5% v/v CO2 to allow macrophages to attach to the
plates before undergoing the fluorescence staining procedure. To
understand the impact of prolonged in vitro culture on primary
rat alveolar macrophages, cells from naïve rats on day 28 of an
in vivo study were harvested and cultured in vitro on 96-well plates
for 24 and 48 h prior to analysis.
Fluorescence Staining and Imaging
Cells were either incubated with amiodarone (0.03–100 μM)
in complete cell culture medium with 1% v/v DMSO for 24
and 48 h alongside internal controls of either untreated cells,
1% v/v DMSO vehicle control, 200 μM carbonyl cyanide-
4-(trifluoromethoxy)phenylhydrazone (FCCP) mitochondrial
activity control or 0.5% v/v Triton X-100 (TX-100) cell death
control. Compound exposure studies were conducted 24 h
after seeding (NR8383) or after differentiation (U937) for cell
lines. For primary macrophages, cells were exposed to com-
pounds 2 h after isolation once the cells had attached to the
96-well plate. For cell health andmorphology assessment, cells
were stained with a dye cocktail containing Hoechst 33342
10 μg/mL, MitoTracker Red 300 nM and Image-It Dead
Green 25 nM (Invitrogen, Renfrewshire, UK) for 30 min.
Cells were washed once with 100 μL PBS and centrifuged at
380 g before fixation with 3.7% w/v paraformaldehyde for
15 min. Fixed cells were stained overnight with Cell Mask
Deep Red (Invitrogen, Renfrewshire, UK) diluted 1:1000 (ac-
cording to the manufacturer’s protocol). Cells were washed
once with PBS as described above before imaging. For the
determination of lipid content, cells were incubated with
HCS LipidTox Phospholipid Red (Invitrogen, Renfrewshire,
UK) diluted 1:1000 (according to the manufacturer’s proto-
col) for 24 h or 48 h. Cells were fixed with 3.7% w/v parafor-
maldehyde containingHoechst 33342 (10 μg/mL) for 20min,
followed by one wash with PBS. Cells were then incubated
with HCS LipidTox Green (Invitrogen, Renfrewshire, UK)
diluted 1:1000 (according to the manufacturer’s protocol) for
30 min at room temperature for detection of neutral lipids.
Cells from both assays were stored at 4°C before sample ac-
quisition. Images were captured using the In Cell Analyser
6000 (GE Healthcare, Little Chalfont, Bucks, UK) with a
40x objective in standard 2D imaging mode with an exposure
time of 0.1 s.
Quantitative High Content Analysis
Image analysis was performed using In Cell Developer
Toolbox v 1.9.2, Level 3 analysis (GE Healthcare, Little
Chalfont, Bucks, UK). For cell health and morphology anal-
ysis, Hoechst 33,342 cell nuclear staining was used to identify
nucleated cells. Cell Mask Deep Red dye is an established cell
delineation tool for cellular imaging and was used to highlight
the cytoplasmic regions within the cells identified. Conversely,
vacuoles within cells were identified based on negative staining
with Cell Mask Deep Red. MitoTracker Red detects the
changes in the mitochondrial membrane potential and accu-
mulates in active mitochondria. Image-It Green Dead is an
impermeant dye to healthy cells that becomes permeant when
the plasma membrane of cells is compromised. These two cell
health stains were reported as fluorescence intensity values.
For lipid content analysis, Hoechst 33342 was used to seg-
ment the cell nuclei as described above and HCS LipidTox
Green was used to identify the cell area. The intercellular
accumulation of phospholipids (phospholipidosis) was
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detected and quantified by cells incubation with phospholipids
conjugated to fluorescent dye – LipidTox Phospholipidosis
Red. The intercellular accumulation of neutral lipids
(steatosis) was detected by LipidTox Green Neutral Lipids
Dye, which has high affinity for neutral lipids. Both stains were
reported as fluorescence intensity values.
Eight quantitative measurements were generated from the
analysis, namely cell area, nuclear area, mitochondrial activi-
ty, cell permeability, vacuole number per cell, vacuole area
per cell, phospholipid content per cell and neutral lipid con-
tent per cell which characterized cell health, morphology and
lipid content. Data represented 9–12 different experiments,
n = 6 wells per experiment, for untreated rat and human cell
lines and 3 different experiments, n = 1 well per experiment,
for amiodarone-exposed cells in 3 different experiments.
Equivalent experiments were performed for primary rat alve-
olar macrophages cultured in vitro for 24 and 48 h from the
BAL of 3 rats, with n = 6 wells per animal. Rat alveolar
macrophages obtained from BAL were also assessed after
2 h of attachment in a 96-well plate without further in vitro
culture from 3 different rats with n = 3 wells per animal.
Secondary Analysis Criteria: Exclusion of Cells
with Reduced Mitochondrial Activity
Criteria to identify dead and/or dying cells were defined so
that these cells could be excluded from the analysis to prevent
morphology and lipid characterization parameters being
impacted by changes induced from cell death. Exposure con-
ditions that reduced the total number of cells imaged to less
than 50% of the number of cells image in control (untreated)
cells were excluded. In the remaining wells, cells with reduced
mitochondrial activity were classified as those possessing less
than two standard deviations below the mean fluorescence
intensity of MitoTracker Red dye in the untreated cell popu-
lation and were excluded from the analysis (Fig. 1).
Mitochondrial activity was selected as a more sensitive marker
over cell permeability as the washing steps within the assay
methodology removed the majority of cells with compromised
cell membrane integrity. Cells exposed to 200 μM FCCP
(potent mitochondrial oxidative phosphorylation uncoupling
agent) were used as an internal assay control to confirm that
the mitochondrial activity exclusion boundary set was appro-
priate. Cell viability has been measured as percentage of cells
with mitochondrial activity above the mean fluorescent value
minus the second standard deviation, out of total number of
cells per well.
Statistical Analysis
Morphology and lipid content median data from repeated
experiments were assessed using the Shapiro-Wilk test for
normality and found to fit a normal (Gaussian) distribution.
One-way ANOVA analysis with Tukey-Kramer multiple
comparison post-hoc tests were used to assess the statistical
significance between the different cell models. Statistical
Fig. 1 Representation of data
analysis approach. Single cell data
was summarised as a frequency
histogram to assess the
reproducibility of untreated cells,
control treatments and sample
treatments (i) Dying cells (defined as
the population with a mitochondrial
activity < mean value minus 2nd
SD) were excluded from the
analysis (a), and the remainder of
the cell population were included
(b). Initial data analysis compared
the median response values (d, e,
f). Elevated cell responses (c and g)
defined as the population of cells
with cell characteristic > mean plus
the 2nd SD from the untreated cell
population were also calculated and
data summarised as elevated
response profiles (ii).
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significance was evaluated at a 95% confidence level
(p < 0.05). All statistical tests were performed using
Graphpad Instat® version 3.06.
RESULTS
Cell Morphology and Lipid Content: Average
Population Data
Individual cell data for each parameter derived from the im-
ages were plotted and morphology and lipid content histo-
grams assessed for normality (Fig. 1). As not all data were
found to fit a normal Gaussian distribution, median values
were obtained for all parameters and used to compare the
different macrophage cell types and the effect of exposure to
amiodarone (Figs. 2 and 3).
Cell morphology was reproducible in each of the models
under investigation. The data ranged from 143–262 µm2
median cell area, 6–11 vacuoles per cell and 7–27% area
occupied by vacuoles in all cell models investigated (Fig. 2).
No significant differences (p > 0.05) were observed for mor-
phology after 24 or 48 h in culture. Whilst a significant differ-
ence (p < 0.05) was observed for cell area between NR8383
and U937 cells for both time points tested, U937 cell area was
not significantly different (p > 0.05) from rodent alveolar mac-
rophages obtained from BAL. Median cell area was more
variable for U937 cells (123–391 µm2) in contrast with
the NR8383 cell line (113–201 µm2) or primary in vivo
alveolar macrophages from BAL (165–265 µm2). This vari-
ability may be due to the PMA-mediated differentiation pro-
cess undergone by the monocytic U937 cells to generate an
alveolar macrophage phenotype. Vacuole number was also
found to be significantly different (p < 0.05) between
Fig. 2 Median morphology
parameters of untreated and
amiodarone-treated rat and human
macrophage cell models. Median
cell area, vacuole number per cell
and percentage of cell area
occupied by vacuoles for untreated
cells (a, c, e) and cells exposed to
10 μM amiodarone (b, d, f).
NR8383 rat macrophage cells
(purple triangle), U937 human
monocyte-derived macrophage
cells (green circles), primary rat
macrophages derived from BAL in
in vitro culture for 24 h or 48 h
(orange diamonds) and primary rat
macrophages derived from BAL
tested immediately after harvesting
from naïve rats after 1 and 7 day
timepoints (blue squares). Each data
point represents the median value
of n = 6 wells per plate. * indicates
p < 0.05.
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NR8383 and U937 cells (6 versus 10) cultured for 48 h but not
between NR8383 and rat primary alveolar macrophages. Rat
alveolar macrophages obtained from BAL from naïve rats
after 1 and 7 days of an in vivo study and characterized imme-
diately after a 2 h attachment period produced the most var-
iable vacuolation. In contrast, BAL cells cultured for 24 and
48 h in vitro displayed more reproducible vacuole characteris-
tics. Whilst intra subject variation for vacuole descriptors was
low for freshly isolated primary rat alveolar macrophages,
variability was greater between the 3 individual rodents
assessed. Untreated cell median lipid content data was repro-
ducible in all models tested (Fig. 3). No significant differences
(p > 0.05) were observed for morphology descriptors between
models with the same cell source after 24 or 48 h.
Additionally, no significant differences (p > 0.05) were ob-
served for either phospholipid or neutral lipid content be-
tween the different cell models investigated.
No significant difference (p > 0.05) was observed between
untreated cells and those exposed to 10 μM amiodarone
(known inducer of phospholipidosis) when comparing median
values, despite observable differences in histogram profiles
(Fig. 1). Average population statistical analysis was not a suit-
ably sensitive descriptor to depict the morphology and lipid
changes observed in cells exposed to amiodarone which im-
pacted less than 20% of the total cell population. Therefore,
an alternative analytical approach which included only the
cell population with elevated characteristics in comparison
with the untreated cells was considered.
Macrophage Responses to Amiodarone: Elevated
Vacuolization and Lipid Content
Profiles describing the cell population were generated to describe
cell health, morphology and lipid content characteristics that
were elevated from untreated cells. Dead/dying cells were elim-
inated as described above and mean nuclear area ± two stan-
dard deviations of the untreated cell population was used as an
exclusion criteria to remove cells with partial or double nuclei
(dividing cells). The remainder of cell health, morphology and
lipid profile descriptors were classified as those that were elevated
from untreated controls (Table I). ‘Elevated’ responses were de-
fined as being greater than two standard deviations above the
mean of the untreated control cell population (Fig. 1). The cell
health inclusion criteria set resulted in >95% of all cells being
included in the analysis and of these, >90% of cells had nuclear
area within two standard deviations of themean (Fig. 4). Analysis
of untreated in vitro cultured U937, NR8383 and BAL-derived
cells indicated that 5–8% of the population cell health, morphol-
ogy and lipid content characteristics were considered ‘elevated’
at two standard deviations above the mean for both 24 and 48 h
time points tested. Elevated cell responses were comparable for
all cell types tested after 24 and 48 h (Fig. 4).
Fig. 3 Median lipid parameters of
untreated vs amiodarone-treated
rat and human macrophage cell
models. Median phospholipid
content and neutral lipid content for
untreated cells (a, c) and cells
exposed to 10 μM amiodarone (b,
d). NR8383 rat macrophage cells
(purple triangle), U937 human
monocyte-derived macrophage
cells (green circles), primary rat
macrophages derived from BAL in
in vitro culture for 24 h or 48 h
(orange diamonds) and primary rat
macrophages derived from BAL
tested immediately after harvesting
from naïve rats after 1 and 7 day
timepoints (blue squares). Each data
point represents the median value
of n = 6 wells per plate. * indicates
p < 0.05.
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In contrast to median value analysis, multi-parameter profile
analysis of the elevated population characteristics revealed an
impact on elevated phospholipid content and cell health
markers as expected for the phospholipidosis inducer, amioda-
rone (Fig. 5). A concentration dependent increase in the number
of cells with elevated mitochondrial activity was observed for
NR8383 and U937 cells after 24 h amiodarone exposure and
NR8383 cells after 48 h exposure. Whilst elevated mitochondri-
al activity was not observed for U937 cells after 48 h exposure
and BAL cells, enhancedmembrane permeability was increased
as a marker of impaired health for these cells. Enhanced phos-
pholipid content was observed for all cells and time points in-
vestigated, and was more pronounced after 48 h exposure in all
cell models. Perturbations in cell morphology, specifically ele-
vated cell area, nuclear/cell area ratio, vacuole number and
vacuole area per cell were observed for all three cell types tested.
In general, these morphological changes were more pro-
nounced after 24 h amiodarone exposure.
Heat maps generated to examine the reproducibility in
terms of elevated parameters between cell passages and exper-
iments indicated a high level of reproducibility in the untreat-
ed cell profile data for all three cell sources investigated
(Fig. 6). Baseline profiles remained consistently reproducible
for all macrophage cell sources tested and were not affected by
passage number, time in culture or experimental variability.
DISCUSSION
The failure rate of inhaled compounds during drug develop-
ment is costly to the pharmaceutical industry [29]. It is not
known whether the foamy macrophage response (highly
Table I Summary of inclusion/exclusion criteria and elevated profile parameters
Parameter Inclusion criteria
Healthy cell inclusion criteria % cells > mean – 2nd SD mitochondrial activity
Normal nuclear area % cells > mean nuclear area - 2nd SD and < mean + 2nd SD of the untreated cell population
Elevated mitochondrial activity % cells > mean mitochondrial activity +2nd SD of the untreated cell population
Elevated membrane permeability % cells > mean membrane permeability +2nd SD of the untreated cell population
Elevated cellular area % cells > mean cell area + 2nd SD of the untreated cell population
Elevated nuclear/cellular area ratio % cells > mean nuclear/cell area ratio + 2nd SD of the untreated cell population
Elevated vacuole number per cell % cells > mean vacuole number per cell +2nd SD of the untreated cell population
Elevated vacuole area per cell % cells > mean vacuole area per cell +2nd SD of the untreated cell population
Elevated phospholipid content % cells > mean phospholipid content per cell +2nd SD of the untreated cell population
Elevated neutral lipid content % cells > mean neutral lipid content per cell +2nd SD of the untreated cell population
Fig. 4 Cell health, morphology
and lipid multi-parameter baseline
profiles. Baseline multi-parameter
charts profiling cell health,
morphology and lipid changes to
the NR8383 rat alveolar
macrophage cell line (a), U937
human monocyte-derived
macrophage cell line (b) and
primary rat macrophages obtained
from BAL (c) after 24 h (black line)
and 48 h (orange line) timepoints.
Data is represented as mean of 3
experiments where n = 6 for each
investigation.
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vacuolated appearance, increased cell size) observed in histolog-
ical lung slices of rats from non-clinical in vivo studies are relevant
to humans and safe exposure levels are set without knowing if
these observations are truly adverse [2–4]. The foamy macro-
phage designation is applied as an umbrella term and is likely to
cover a broad number of cell responses which manifest in a
vacuolated appearance, but reflect different cell phenotypes
with different impacts on airway pathophysiology [3].
Whilst in vitro approaches for predicting drug safety are
used non-clinically in the pharmaceutical industry, multi-
parameter screens combining viability, activation, functional-
ity and morphology endpoints are not used routinely.
Furthermore, morphological assessment by low resolution
and confocal microscopy provides a crude description of the
phenotype with little detail regarding the cellular changes [3].
Multi-parameter in vitro assessment of phenotypic alveolar
macrophage responses may allow a more detailed under-
standing of pathological lung responses which can be
correlated to morphological changes observed in the rat lung
to help inform more detailed safety assessment.
This paper describes methodology for assessing changes
in cell health, morphology and lipid content of in vitro and
ex vivo alveolar macrophage cell models using a high con-
tent image analysis technique. Alveolar macrophage re-
sponses to drug challenge in vivo may impact only a small
percentage of the total cell population [1, 2] and this was
also observed in the in vitro studies. As a result, cellular
responses in vitro may be overlooked when considering sin-
gle, average data descriptors. The high content image
analysis methodology described in this paper captures mul-
tiple parameters for individual cells, enabling analysis of a
subset of the population of cells that respond to the drug
stimulus. Amiodarone was used as a model drug to gener-
ate morphology and lipid profile responses consistent with
the established phenotypic response of phospholipidosis it
induces in alveolar macrophages [30–35].
Fig. 5 Cell health, morphology
and lipid multi-parameter profiles
after amiodarone exposure. Multi-
parameter charts profiling cell
health, morphology and lipid
changes to the NR8383 rat alveolar
macrophage cell line (a, b), U937
human monocyte-derived
macrophage cell line (c, d) and
primary rat macrophages obtained
from BAL (e, f) after 24 h (a, c, e)
and 48 h (b, d, f) exposure to 0–
10 μM amiodarone. Data is
represented as mean of 3
experiments where n = 6 for each
investigation.
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Baseline profiles were established for the alveolar macro-
phage cell line NR8383, human PMA-differentiated mono-
cyte cell line U937 and rat alveolar macrophages obtained
from BAL immediately after isolation and after up to 48 h
in vitro culture. With the exception of median cell area, un-
treated cells showed comparable cell morphology and lipid
content parameters for both average and elevated cell re-
sponse analysis methods between rat and human models test-
ed. Cell characteristics investigated for all three in vitro models
were highly reproducible and in accordance with observations
from the macrophages obtained from the BAL of rats which
had been exposed to air controls in inhalation toxicology study
protocols, indicating their suitability for studying alveolar
macrophage responses in vitro. As anticipated, morphometry
was more variable between the different cell models after ami-
odarone treatment, however changes in cell health and phos-
pholipid content were evident in all models as expected for
ce l l s exposed to a compound known to induce
phospholipidosis. Further work is required to assess the vari-
ability in morphological response between different cell
models and whether this reflects differences between species.
Interspecies differences in alveolar macrophage cell diam-
eter between rats and humans have been reported [36–39],
where human alveolar macrophages were found to be signif-
icantly larger (p < 0.05) than for rats (21.2 μm vs 13.1 μm). It
has been hypothesized that the phagocytic capabilities of these
cells may differ between species due to inherent or acquired
differences in alveolar macrophage size [36]. Additionally,
humans possess a greater number of alveolar macrophages
in the airways in comparison with rats [37]. These differences
are likely to reflect the different respiratory species - as obligate
nose breathers, rats are exposed to fewer airway particulates
than human lungs [37]. Interspecies differences in inflamma-
tory pathway mediators (NO, TNFα) and phagocytic activity
have also been demonstrated between rat and human alveolar
macrophages [38, 39]. Characterising the phenotypic and
functional responses of foamy alveolar macrophages in rat
and human is key to developing robust models for accurate
inhaled safety prediction in humans.
As alveolar macrophage responses are complex, a single
parameter assay is unlikely to be adequately descriptive of
the different types of ‘foamy’ alveolar macrophage responses
Fig. 6 Heatmap indicating experimental variability. Variability of profile parameters for cells exposed to 0–10μM amiodarone for 24 and 48 h for the NR8383 rat
alveolar macrophage cell line (a), U937 human monocyte-derived macrophage cell line (b) and primary rat macrophages obtained from BAL (c). Each square
represents one experiment. The colour gradient sets the lowest value for each given parameter in the heat map (bright green), highest value (bright red) and mid-
range values (black) with a corresponding gradient between these extremes.
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to drugs modulating airway biology. The multi-parameter
assay approach described in this paper permits a more de-
tailed characterization of how inhaled drugs impact airway
macrophage responses and how these develop with duration
of and concentration of exposure. A major challenge of this
approach is devising an appropriate analysis format for the
copious individual cell data generated by the high content
assay technique. This is particularly important when using this
technique as a screening tool for the prediction of drug safety.
It has been demonstrated previously that hierarchical cluster-
ing of similar multi-parameter data sets has proven an effec-
tive and unbiased method of grouping compounds that gen-
erate similar phenotypic profiles in cells in vitro [40, 41].
Future work will focus on employing the methodologies de-
scribed to a broader set of reference compounds that are
established to induce alveolar macrophage responses to ascer-
tain if these techniques are sufficiently sensitive to discern dif-
ferent ‘foamy’ alveolar macrophage phenotypes.
CONCLUSION
A high content analysis methodology was successfully devel-
oped and applied to characterizing the morphology and lipid
content of NR8383 andU937 cells andmacrophages from rat
lungs. Cell vacuolisation and lipid content were similar be-
tween rat and human models for cells in culture. All alveolar
lung macrophage cell models responded to challenge with
amiodarone, a known inducer of phospholipidosis, but detec-
tion of these required analysis of cell sub-populations (the pro-
portion of cells with elevated vacuolation or lipid content)
rather than average population data which was insensitive to
the changes observed. Future work will focus on establishing
morphological and lipid profiles of in vitro alveolar macro-
phages following exposure to a broad range of compounds
known to induce macrophage responses (and selected con-
trols), and comparing these to effects in vivo, and complemen-
tary pathway analysis to explore the foamy macrophage phe-
notype. This work has shown that the multi-parameter meth-
odology has the potential to offer an early non-clinical screen-
ing tool to predict the safety of candidate inhaled medicines.
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